PL328771A1 - Derivatives of 4-aminopyrimidine, therapeutic agents containing such compounds, their application and method of obtaining such compounds - Google Patents
Derivatives of 4-aminopyrimidine, therapeutic agents containing such compounds, their application and method of obtaining such compoundsInfo
- Publication number
- PL328771A1 PL328771A1 PL97328771A PL32877197A PL328771A1 PL 328771 A1 PL328771 A1 PL 328771A1 PL 97328771 A PL97328771 A PL 97328771A PL 32877197 A PL32877197 A PL 32877197A PL 328771 A1 PL328771 A1 PL 328771A1
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- aminopyrimidine
- derivatives
- obtaining
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1996108631 DE19608631A1 (en) | 1996-03-06 | 1996-03-06 | New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives |
| DE19629652A DE19629652A1 (en) | 1996-03-06 | 1996-07-23 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL328771A1 true PL328771A1 (en) | 1999-02-15 |
Family
ID=26023531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL97328771A PL328771A1 (en) | 1996-03-06 | 1997-03-03 | Derivatives of 4-aminopyrimidine, therapeutic agents containing such compounds, their application and method of obtaining such compounds |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0885226A1 (en) |
| JP (1) | JP2000506847A (en) |
| KR (1) | KR19990087550A (en) |
| CN (1) | CN1212695A (en) |
| AU (1) | AU710274B2 (en) |
| BG (1) | BG102708A (en) |
| BR (1) | BR9708312A (en) |
| CA (1) | CA2243994A1 (en) |
| CZ (1) | CZ281798A3 (en) |
| DE (1) | DE19629652A1 (en) |
| EE (1) | EE9800277A (en) |
| HU (1) | HUP9901820A3 (en) |
| IL (1) | IL125404A0 (en) |
| NO (1) | NO984084D0 (en) |
| NZ (1) | NZ331546A (en) |
| PL (1) | PL328771A1 (en) |
| SK (1) | SK120598A3 (en) |
| TR (1) | TR199801749T2 (en) |
| WO (1) | WO1997032881A1 (en) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| DK1676845T3 (en) | 1999-11-05 | 2008-09-15 | Astrazeneca Ab | New quinazoline derivatives |
| WO2004113334A1 (en) | 2003-06-24 | 2004-12-29 | Neurosearch A/S | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CA2598489A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
| US8710104B2 (en) | 2008-11-07 | 2014-04-29 | Triact Therapeutics, Inc. | Catecholic butanes and use thereof for cancer therapy |
| US8530650B2 (en) * | 2008-12-01 | 2013-09-10 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer |
| JP2012518657A (en) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Combined anticancer treatment |
| EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
| WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012520893A (en) | 2009-03-18 | 2012-09-10 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Combination cancer treatment comprising administration of an EGFR inhibitor and an IGF-1R inhibitor |
| WO2011058164A1 (en) | 2009-11-13 | 2011-05-19 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| EP2751285B2 (en) | 2011-08-31 | 2020-04-01 | Genentech, Inc. | Method for sensitivity testing of a tumour for a egfr kinase inhibitor |
| AU2012321248A1 (en) | 2011-09-30 | 2014-04-24 | Genentech, Inc. | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| CA2941010A1 (en) | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancer therapy |
| US20160051556A1 (en) | 2013-03-21 | 2016-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression |
| US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| CN107223163A (en) | 2014-12-24 | 2017-09-29 | 豪夫迈·罗氏有限公司 | Methods for treatment, diagnosis and prognosis of bladder cancer |
| PT3558955T (en) | 2016-12-22 | 2021-10-19 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| CN111051306B (en) | 2017-09-08 | 2023-01-03 | 美国安进公司 | Inhibitors of KRAS G12C and methods of use thereof |
| MA52496A (en) | 2018-05-04 | 2021-03-10 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
| MX2020010836A (en) | 2018-05-04 | 2021-01-08 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
| MA52564A (en) | 2018-05-10 | 2021-03-17 | Amgen Inc | KRAS G12C INHIBITORS FOR CANCER TREATMENT |
| EP3802535B1 (en) | 2018-06-01 | 2022-12-14 | Amgen, Inc | Kras g12c inhibitors and methods of using the same |
| EP3802537A1 (en) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
| JP7516029B2 (en) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds |
| AU2019384118A1 (en) | 2018-11-19 | 2021-05-27 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| BR112021011989A2 (en) | 2018-12-20 | 2021-09-08 | Amgen Inc. | KIF18A INHIBITORS |
| CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| EP3897855B1 (en) | 2018-12-20 | 2023-06-07 | Amgen Inc. | Kif18a inhibitors |
| JP2022513971A (en) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Heteroarylamide useful as a KIF18A inhibitor |
| CA3130080A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| EP3930845A1 (en) | 2019-03-01 | 2022-01-05 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| MX2021014126A (en) | 2019-05-21 | 2022-01-04 | Amgen Inc | FORMS IN SOLID STATE. |
| EP4007756A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Kif18a inhibitors |
| CN114391012A (en) | 2019-08-02 | 2022-04-22 | 美国安进公司 | Pyridine derivatives as KIF18A inhibitors |
| WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| CA3146693A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| AU2020369569A1 (en) | 2019-10-24 | 2022-04-14 | Amgen Inc. | Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer |
| CR20220240A (en) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | RAS INHIBITORS |
| PE20221278A1 (en) | 2019-11-04 | 2022-09-05 | Revolution Medicines Inc | RAS INHIBITORS |
| CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4055017A1 (en) | 2019-11-08 | 2022-09-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| CA3161156A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| EP4058453A1 (en) | 2019-11-14 | 2022-09-21 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| JP2023505100A (en) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | Covalent RAS inhibitors and uses thereof |
| IL294484A (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines Inc | Dosage for shp2 inhibitor and methods for treating cancer |
| BR112022025550A2 (en) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | METHODS TO DELAY, PREVENT, AND TREAT ACQUIRED RESISTANCE TO RAS INHIBITORS |
| MX2023002248A (en) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations. |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| US20240051956A1 (en) | 2020-12-22 | 2024-02-15 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| MX2023012060A (en) | 2021-04-13 | 2024-01-22 | Nuvalent Inc | Amino-substituted heterocycles for treating cancers with egfr mutations. |
| JP2024517845A (en) | 2021-05-05 | 2024-04-23 | レボリューション メディシンズ インコーポレイテッド | RAS Inhibitors for Cancer Treatment |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| BR112023022819A2 (en) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATES AND METHODS FOR TREATING CANCER IN A SUBJECT, FOR TREATING A DISORDER AND FOR INHIBITING A RAS PROTEIN IN A CELL |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| TW202340214A (en) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (en) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | Method for treating immune refractory lung cancer |
| IL317476A (en) | 2022-06-10 | 2025-02-01 | Revolution Medicines Inc | Macrocyclic ras inhibitors |
| WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| DE4431867A1 (en) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation |
-
1996
- 1996-07-23 DE DE19629652A patent/DE19629652A1/en not_active Ceased
-
1997
- 1997-03-03 HU HU9901820A patent/HUP9901820A3/en unknown
- 1997-03-03 EE EE9800277A patent/EE9800277A/en unknown
- 1997-03-03 NZ NZ331546A patent/NZ331546A/en unknown
- 1997-03-03 SK SK1205-98A patent/SK120598A3/en unknown
- 1997-03-03 WO PCT/EP1997/001057 patent/WO1997032881A1/en not_active Application Discontinuation
- 1997-03-03 CN CN97192787A patent/CN1212695A/en active Pending
- 1997-03-03 KR KR1019980706987A patent/KR19990087550A/en not_active Application Discontinuation
- 1997-03-03 JP JP9531444A patent/JP2000506847A/en active Pending
- 1997-03-03 EP EP97907066A patent/EP0885226A1/en not_active Ceased
- 1997-03-03 AU AU19251/97A patent/AU710274B2/en not_active Ceased
- 1997-03-03 CA CA002243994A patent/CA2243994A1/en not_active Abandoned
- 1997-03-03 IL IL12540497A patent/IL125404A0/en unknown
- 1997-03-03 BR BR9708312A patent/BR9708312A/en not_active IP Right Cessation
- 1997-03-03 CZ CZ982817A patent/CZ281798A3/en unknown
- 1997-03-03 PL PL97328771A patent/PL328771A1/en unknown
- 1997-03-03 TR TR1998/01749T patent/TR199801749T2/en unknown
-
1998
- 1998-08-20 BG BG102708A patent/BG102708A/en unknown
- 1998-09-04 NO NO984084A patent/NO984084D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2243994A1 (en) | 1997-09-12 |
| IL125404A0 (en) | 1999-03-12 |
| CN1212695A (en) | 1999-03-31 |
| EP0885226A1 (en) | 1998-12-23 |
| AU1925197A (en) | 1997-09-22 |
| NO984084L (en) | 1998-09-04 |
| DE19629652A1 (en) | 1998-01-29 |
| JP2000506847A (en) | 2000-06-06 |
| EE9800277A (en) | 1999-02-15 |
| KR19990087550A (en) | 1999-12-27 |
| TR199801749T2 (en) | 1998-12-21 |
| AU710274B2 (en) | 1999-09-16 |
| WO1997032881A1 (en) | 1997-09-12 |
| SK120598A3 (en) | 1999-06-11 |
| HUP9901820A2 (en) | 1999-09-28 |
| NZ331546A (en) | 2000-03-27 |
| CZ281798A3 (en) | 1999-02-17 |
| BR9708312A (en) | 1999-08-03 |
| BG102708A (en) | 1999-09-30 |
| HUP9901820A3 (en) | 2001-10-29 |
| NO984084D0 (en) | 1998-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL328771A1 (en) | Derivatives of 4-aminopyrimidine, therapeutic agents containing such compounds, their application and method of obtaining such compounds | |
| PL330841A1 (en) | Benzosulphonic derivatives, method of obtaining them and therapeutic agents containing such derivatives | |
| PL317930A1 (en) | Oxalydine compounds, method of obtaining them and therapeutic agents | |
| PL329440A1 (en) | Derivatives of d-proline, method of obtaining them and therapeutic agent containing such compounds | |
| PL321201A1 (en) | Derivatives of 4-hydroxypiepridine, method of obtaining them and therapeutic agents containing such derivatives | |
| PL313433A1 (en) | Derivatives of benzazepin-, benzoxazepin- and benzothiazepin-n-acetic acids, method of obtaining them and therapeutic agents containing such derivatives | |
| PL318277A1 (en) | Novel substituted axazolydinones, method of obtaining and drugs containing them | |
| PL320952A1 (en) | Cycloalkanon pyridines, method of obtaining and therapeutic agents containing them | |
| PL311999A1 (en) | Piperazine derivatives, therapeutic agents containing them and method of obtaining such derivatives | |
| PL331863A1 (en) | 7alpha-(xi-aminoalkyl)-estrathienes, method of obtaining them, pharmacautic preparations containing such compounds and their application in production of therapeutic agents | |
| PL332432A1 (en) | Oxadiazoles, method of obtaining them as well as their application as therapeutic agents | |
| PL316613A1 (en) | Novel derivatives of piperazine, methods of obtaining them and agents containing such derivatives | |
| PL329274A1 (en) | Novel derivatives of isoquinolin-3-carboxylamides, method of obtaining them, their application, pharmaceutic agent containing them and method of obtaining such pharmaceutic agent | |
| PL324436A1 (en) | Novel derivatives of oxazolydinone, method of obtaining them and therapeutic agents containing such compounds | |
| PL321003A1 (en) | Derivatives of piperasine, drugs containing them, their application and methods of obtaining them | |
| PL313633A1 (en) | Ceramid type compounds, method of obtaining them and their application | |
| PL307669A1 (en) | Benzimidazoles, therapeutic agents containing them and method of obtaining such compounds | |
| PL338143A1 (en) | Derivatives acylpiperazinylpyrimidines, method of obtaining and drugs containing them | |
| ZA971964B (en) | Azolobenzazepine derivatives and compositions and method of use thereof. | |
| PL325322A1 (en) | Novel substituted amine compounds, method of obtaining them and therapeutic agent | |
| PL323177A1 (en) | Azacycloalcane derivatives, method of obtaining them and their application for therapeutic purposes | |
| PL322802A1 (en) | Derivatives of 10,13,15-trioxatricyclo[9.2.1.1]-pentadecanone, method of obtaining them and therapeutic agents containing such compounds | |
| ZA9711168B (en) | New therapeutic application of pyrrole derivatives. | |
| PL330257A1 (en) | Novel heterocyclic derivatives of benzocycloalkene, method of obtaining them and therapeutic agent | |
| PL316486A1 (en) | Novel sulphonamides, method of obtaining them and therapeutic agent containing them |